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Abstract
For a few years, a series of traditionally tropical mosquito-borne diseases, such as chikungunya fever and dengue, have posed challenges to
national public health authorities in the European region. Other diseases have re-emerged, e.g. malaria in Greece, or spread to other
countries, e.g. West Nile fever. These diseases are reportable within the European Union (EU), and the European Centre for Disease
Prevention and Control collects information in various ways to provide EU member states with topical assessments of disease threats, risks
and trends for prompt and appropriate public health action. Using disease-specific expert networks, the European Surveillance System
(TESSy) collects standardized comparable information on all statutory communicable diseases in a database. In addition, the event-based
surveillance aims to detect potential public health threats early, and to allow timely response and support to blood deferral decisions for
pathogens that can be transmitted through blood donation. Laboratory capacity for early detection is implemented through external quality
assessments. Other activities include the development of guidelines for the surveillance of mosquito vectors, and the production of regularly
updated maps on the currently known occurrence of mosquito vector species.
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Introduction
Vector-borne diseases pose a special challenge to public health
authorities in Europe, owing to their complex nature, i.e. the
biological complexity of their transmission system. Most of
these diseases also show particular epidemiological features,
such as seasonality and periods of pathogen persistence
without detection of the disease (asymptomatic human
infections, presence of reservoir hosts, and persistence in
vectors and their progeny). Many aspects of the transmission
cycle are strongly influenced by environmental conditions,
which are changing (including climate, agricultural practices,
land use, and urbanization), and might allow for (re-)emer-
gence or (re-)introduction in a suitable setting [1]. Moreover,
vector-borne diseases tend to become ‘globalized’ through
increasing population mobility and migration, travel, and trade,
which results in the rapid and worldwide spread of vectors and
the pathogens that they transmit [2].
In the European region, tropical mosquito-borne diseases
(MBDs), such as chikungunya (CHIK) fever, dengue, malaria,
and West Nile (WN) fever, have attracted recent attention: on
the one hand, travel-related cases of some of these diseases,
such as dengue, are increasingly being recorded in Europe; and
on the other hand, the risk of local transmission has increased
with the recent spread of invasive Aedes mosquitoes such as
Aedes albopictus, a potential vector of CHIK and dengue
viruses. In the European Union (EU), these diseases are
included in the list of the communicable diseases to be covered
by epidemiological surveillance [3]. The European Centre for
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Disease Prevention and Control (ECDC) collects information
in various ways to provide EU member states with topical
assessments of disease threats, risks and trends for prompt
and appropriate public health action.
Types of Surveillance Activity
To understand and assess the risks associated with different
MBDs in member states, data are needed on disease, pathogen
presence (in reservoir hosts), and the occurrence of vectors [3].
An overview of the types of surveillance activity and the number
of outputs per year for malaria, dengue, CHIK fever, WN fever
and Rift Valley fever (RVF) since 2009 is presented in Table 1.
Indicator-based surveillance
The European Surveillance System (TESSy) comprises a
database and disease-specific expert networks, which collect
standardized comparable information on all statutory com-
municable diseases and surveillance systems across the EU
member states and European Economic Area (EEA) coun-
tries [4]. The ECDC Annual Epidemiological Report, which
has been published since 2007, gives a yearly overview of
the situation regarding communicable diseases in the EU and
EEA countries. It provides information on trends and
seasonality, age and gender distributions, and relevant
events [5].
Event-based surveillance
Event-based surveillance is part of the ECDC mandate. It aims
to detect potential public health threats early, and allow for
timely responses. The sources of information include several
websites and a large number of web pages retrieved through
specialized search engines [6]. Threats are summarized in
threat reports; threats potentially affecting more than one
member state lead to joint risk assessments, such as those on
the 2012 dengue outbreak in Madeira [7].
Other epidemiological reports
The ECDC’s programme on MBDs also develops comple-
mentary activities and outputs, such as expert consultations
and field missions, guidelines, and technical reports. The aim of
the programme is to better understand the triggers of MBD,
enhance the surveillance of mosquito vectors and the diseases
that they transmit, improve communication about MBD risks,
and develop the appraisal of vector control strategies. For
example, the ECDC recently provided European countries
with guidelines for the surveillance of invasive mosquitoes, and
supports the production of regularly updated maps on the
currently known occurrence of mosquito vector species (e.g. T
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A. albopictus and Aedes aegypti) at regional administrative levels
(NUTS3), based on published and expert data in the EU [8,9].
Laboratory capacity for surveillance in Europe
The diagnostic capacity within Europe is a key component of
surveillance for the early detection and surveillance of these
MBDs. For some viruses, such as RVF, CHIK and yellow
fever (YF) viruses, there are no or a very limited number of
commercial assays. For this reason, the ECDC is funding the
European Network for Diagnosis of Viral Imported Diseases,
which provides support related to laboratory diagnostics and
assists EU member states, candidate countries and the EEA
countries in detecting and characterizing these pathogens.
The network organizes external quality assessments (EQAs),
and offers advice and support to the EQA participants to
help them improve their techniques and procedures. In
recent years, EQAs have been organized for YF, WN fever,
dengue, CHIK fever, and, latterly, RVF; 30 laboratories,
including 22 laboratories from Europe, have participated in
these [10–13].
WN Fever Surveillance
The first outbreak of WN fever, which is caused by an
arbovirosis initially identified in Africa in the 1930s, was
reported in horses and humans in France in the 1960s [14].
After that, the disease was considered to constitute a minor
risk for humans and horses in Europe, because only a few cases
appeared sporadically. However, the disease re-emerged in
1996, with a large outbreak in humans in Romania [15]. In
1999, the disease was, for the first time, detected in New York
city, and it then spread towards the Americas [14]. Owing to
the huge impact of the disease on human and animal health in
North America, and to the recurrent detection of cases in
humans and/or horses in Europe and the Mediterranean basin,
WN virus infection was included in 2008 in the list of notifiable
diseases in the EU [4]. In 2011, 24 EU/EEA countries reported
cases in TESSy. The reporting is compulsory in 19 member
states. It is comprehensive (based on cases occurring within
the whole population) and passive (physicians, laboratories or
hospitals take the initiative to report data to the health
department) in 18 EU countries. Sixteen countries use the EU
case definition for surveillance to report the data. Some
countries have implemented an active surveillance system from
June to October in areas considered to be at risk when
mosquitoes are active, e.g. southern France and Veneto Region
in Italy [16].
Data from the indicator-based surveillance are collected
retrospectively on a yearly basis. Because WN fever is
detected every year in several EU countries, and can be
transmitted through blood transfusion and organ transplanta-
tion, it was necessary to develop a complementary system for
the collection of information about WN cases and its rapid
communication. This information is required for timely
implementation of: (i) personal and collective response
measures in the case of an outbreak; and (ii) safety measures
for blood donations for people living in or with travel history
to areas with ongoing transmission of WN virus to humans
[17]. Thus, the ECDC launched the WN mapping project in
2011. During the transmission season, weekly updates of the
number and spatial distribution of WN human cases reported
in the EU, neighbouring countries and countries bordering the
Mediterranean Sea are made publicly available on the ECDC
website. WN cases are collected through the event-based
surveillance and validated with the countries’ health author-
ities. In 2011, only confirmed cases, as per the EU case
definition, were included in the maps for the EU countries; in
2012, both confirmed and probable cases with positive
laboratory test results were displayed. As well as improving
the timeliness and availability of information about the WN
cases, this tool has contributed greatly to improving the
awareness of the people involved in the surveillance and the
coverage of the surveillance system. Actually, more countries
and more areas within countries detected cases in 2012 than in
2011 and 2010, even though the total number of cases was
much lower than in 2010 and slightly higher than in 2011. By
improving the reporting of WN cases in Europe, this tool and
its developments will help to achieve the objective of WN
fever surveillance, i.e. ‘to ensure early identification of cases in
humans and animals at risk, to implement protective measures
in good time’ [18]. In the area of research, it also allows
hypothesis generation from a wider knowledge base in cases
where the occurrence of WN outbreaks was considered to be
quite unpredictable.
Dengue and CHIK Fever Surveillance
Dengue is endemic in most of tropical and subtropical regions,
including several European Overseas Territories. Dengue is by
far the most important mosquito-borne viral disease affecting
humans worldwide; tens of millions of cases occur each year,
resulting in approximately 20 000–25 000 deaths, mainly in
children. CHIK fever is widespread in tropical and subtropical
regions in Africa and Asia, and is absent from the Americas.
A. aegypti is not present in the EU, with the exception of
Madeira, where it was identified in 2005 [19]. The species is
also present around the Black Sea [9]. However, A. albopictus,
a secondary vector of dengue and an important vector of
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CHIK virus, is well established and expanding in several
European countries [9]. In recent years, locally acquired cases
of dengue and CHIK fever have been reported, and have
shown that such tropical vector-borne disease can also spread
in Europe in areas where competent Aedes mosquito vectors
are present. An outbreak of CHIK fever occurred in 2007 in
Italy, two indigenous cases were detected in 2010 in France
[20,21], and several locally acquired cases of dengue occurred
in Croatia and France in 2010 [22,23]. In October 2012,
Madeira (Portugal) reported a large outbreak of dengue
(DEN 1) infection [7].
For dengue andCHIK fever, respectively, 22 and 20 countries
out of 30 EU/EEA countries report data to TESSy. Dengue
reporting is compulsory in 19 countries, and 11 countries use
the EU case definition for surveillance to report the data. CHIK
fever is reported from ten countries according to the EU case
definition. In most countries, data are passively collected
through laboratories, physicians, and hospitals. Some countries,
such as France and Italy, implement active surveillance during the
mosquito season from June to October [16,24,25].
There are large variations in the notification rate for dengue
between countries, reflecting the travel destination preferences
of EU nationals. The overall notification rate for dengue was
quite stable in 2008 and 2009, at 0.11 per 100 000 as compared
with 0.25 per 100 000 in 2010; this was directly linked to an
increase in the number of travel-related dengue cases. In that
year, there was a significant increase in dengue transmission in
several tropical countries, mainly in the Caribbean, Central/
South America, and Asia. Travellers were at significantly more
risk of acquiring dengue, and could also have contributed to its
spread, as reported in France or Croatia [22,23]. Most of the
cases were reported in the 25–44-year and 45–60-year age
groups, who are possibly more inclined to travel. Interestingly,
the notification ratewas higher inmales than in females for these
3 years. The overall notification rate for CHIK fever was lower
than that for dengue (0.01–0.02 per 100 000) for the years
2008–2010, andmost of the caseswere reported in the same age
groups. Unlike with dengue, the overall notification rate was
higher in females than in males in the last 4 years. The numbers
of patients with CHIK fever reported from June to September in
countries at risk of local transmission was ten times higher in
2010 than in the other years.
YF Surveillance
YF, a viral disease that is also transmitted by Aedes mosquitoes
in sub-Saharan Africa and in South America, is another
reportable disease in the EU. Since 2007, one imported case
has been reported in the EU, in 2009, with an unclear travel
history [5]. Although imported cases are rare, non-vaccinated
travellers visiting affected areas without the effective protec-
tion of YF vaccination expose themselves to risk of infection.
RVF Surveillance
With the expansion of the geographical distribution of RVF
virus in Africa and in the Middle East, the disease requires
attention, because suitable host, vectors and environmental
conditions for additional epidemics probably exist on other
continents. The disease at the human–animal interface affects
primarily animals, and animal cases have to be reported to the
Office International des Epizooties. Seventeen of 30 EU/EEA
countries report human cases in TESSy. The reporting is
compulsory in 16 countries, and nine countries use the EU
2008 case definition. No human RVF cases were reported in
continental Europe in 2007, but a few cases were reported
from Mayotte, a French department in the Indian Ocean, in
2008 during an outbreak in the region [26].
Malaria Surveillance
Malaria is caused by one of the five Plasmodium parasites:
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale,
Plasmodiummalariae, and Plasmodium knowlesi. It is an old disease
of continental Europe, and was eliminated in the 1970s by a
combination of early detection and treatment of cases,mosquito
vector control by indoor residual spraying of houses and
larviciding of breeding sites, environmental modifications, and
human habitat modifications. In the countries directly neigh-
bouring Europe,malaria transmission is currently steeply declining,
and there is a target of malaria elimination by 2015 [27].
Twenty-six of 30 EU/EEA countries report data to TESSy,
and in 23 countries the reporting is compulsory. Seventeen
countries use the EU case definition for surveillance to report
the data, which are, in most countries, passively collected
through laboratories, physicians, and hospitals. Over the last
5 years (2006–2010), no clear trend has been observed in the
number of reported malaria cases, which has fluctuated around
one per 100 000 population per year. Nearly all malaria cases
(>99%) are reported as imported—the definition of imported
cases refers to cases imported to continental Europe—and are
primarily notified by EU/EEA countries that have strong ties
with endemic areas. The seasonality and age distribution most
likely reflect travel patterns to malaria-endemic countries.
Outside continental Europe, some countries or territories are
endemic for malaria (e.g. Mayotte and French Guiana), and for
these, data are not collected through TESSy.
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Sporadic local transmission of malaria is reported in the EU,
but a specific problem appeared in Greece, where the
presence of seasonal workers from P. vivax-endemic countries
in agricultural areas where competent Anopheles species are
present resulted in onwards local transmission [28–32]. To
cope with this specific problem, active case detection has been
set up to enable early detection of symptomatic cases among
these migrants, and to decrease the possibility of onwards
transmission from imported cases. Likewise, in Germany an
increase in the number of malaria cases imported from
Pakistan was reported in 2012, but this did not result in
onwards transmission [33]. Currently, migration flows and
increasing international travel result in malaria importations
into Europe. Local transmission of P. vivax remains possible in
the EU, where the Anopheles vectors are present, and stresses
the need for surveillance, preparedness and prevention within
EU and EEA countries, including improvements in access to
healthcare for seasonal workers.
Conclusion
The future challenge in implementing mosquito and MBD
surveillance and reporting is to improve and harmonize EU-
wide coverage and data collection. In addition, coordinated
and enhanced human, veterinary, entomological and environ-
mental surveillance is needed in all member states at risk of
MBDs, together with increased scientific and technical support
from the ECDC. Sustainability of surveillance is a major
challenge for these diseases with unpredictable occurrence. In
addition, surveillance of human cases needs to be backed up by
the implementation of surveillance of vectors and the assess-
ment of vector control measures.
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